Kymera Therapeutics

Kymera Therapeutics

Yahoo Finance • 2 days ago

American Express, Biogen upgraded: Wall Street's top analyst calls

American Express, Biogen upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by... Full story

Yahoo Finance • 2 days ago

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

Quick Read SK hynix surged 13% on its Nasdaq debut, raising $26.5 billion in what stands as the largest U.S. equity sale by a foreign company ever. Circle Internet Group (CRCL) surged 15% on OCC bank approval as Capital One (COF) earned a... Full story

Yahoo Finance • 2 days ago

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction val... Full story

Yahoo Finance • 12 days ago

Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Kymera Therapeutics now carries an updated fair value estimate of US$123.76, a modest step up from US$119.19 that has drawn attent... Full story

Yahoo Finance • 20 days ago

Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more

Check out the companies making the biggest moves midday: Kymera Therapeutics — The biotech stock surged 17% after Kymera enrolled in a Phase 2b Broaden2 trial for its KT-621 drug, which aims to treat atopic dermatitis. BlackBerry — Shares... Full story

Yahoo Finance • 20 days ago

Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth

(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera sinc... Full story

Yahoo Finance • 2 months ago

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 2 months ago

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

Boxer Capital Management increased its stake in Kodiak Sciences(NASDAQ:KOD) during the first quarter, adding 225,000 shares in a transaction estimated at $5.81 million based on quarterly average pricing, according to a May 15, 2026, SEC fi... Full story

Yahoo Finance • 2 months ago

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 2 months ago

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases KT-621 parallel Phase 2b trials, BROADE... Full story

Yahoo Finance • 2 months ago

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Seaport Research upgraded AMD (AMD) to... Full story

Yahoo Finance • 2 months ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technologies, Reddit, and More

Quick Read Stocks rallied on Tuesday as oil traded lower and some strong first-quarter earnings results hit the tape. Earnings for the first quarter are winding down, but 85% of S&P 500 companies beat Wall Street expectations. Needless to... Full story

Yahoo Finance • 3 months ago

A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The latest move in Kymera Therapeutics (KYMR) stock has been driven by the FDA granting Fast Track designation to KT-621 fo... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics Gets FDA Fast Track Status For KT-621 In Asthma

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) on Monday said the U.S. Food and Drug Administration has granted Fast Track designation to its investigational drug KT-621 for the treatment of moderate to severe eosinophilic asthma. KT-621 is... Full story

Yahoo Finance • 3 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 4 months ago

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expect... Full story

Yahoo Finance • 4 months ago

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story

Yahoo Finance • 4 months ago

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a new position in Terns Pharmaceuticals(NASDAQ:TERN), acquiring 375,000 shares in a transaction estimated at $15.15 million based on quarterly average pricing. What Happened B... Full story

Yahoo Finance • 5 months ago

Kymera (KYMR) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Feb. 26, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Nello MainolfiChief Medical Officer — Jared GollobChief Financial Officer — Bruce Jacobs Need a quote from a Motle... Full story

Yahoo Finance • 7 months ago

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story